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Objective: The purpose of this study was to prospectively evaluate the clinical and
hemodynamic performance of the Mosaic bioprosthesis (Medtronic, Inc, Minneap-
olis, Minn).
Methods: The stented porcine bioprosthesis combines the amino-oleic acid antimin-
eralization treatment and the zero-pressure differential fixation technique for im-
proved tissue durability. From February 1994 to May 1999, a total of 561 patients
underwent valve replacement with the Mosaic bioprosthesis at 5 centers in Europe:
461 in the aortic and 100 in the mitral position. There were 261 women and 300
men; mean age at implantation was 70 years (range, 23-89 years). Mean follow-up
was 2.9 years (range, 0-6.2 years), with a total follow-up of 1710.1 patient-years.
Results: Postoperative mortality was 4.2% per patient-year, including a valve-
related mortality of 0.4% per patient-year. The freedom from event rates in the
aortic position at 5 years and in the mitral position at 4 years were, respectively,
96.6%  1.1% and 94.9%  3.3% for primary thromboembolism, 96.4%  5.0%
and 87.1% 4.8% for antithromboembolic-related hemorrhage, 99.1% 0.5% and
100% for thrombosed prosthesis, 98.8%  1.2% and 100% for structural valve
deterioration, 98.8%  0.7% and 100% for nonstructural dysfunction, 98.4% 
0.6% and 94.4%  3.8% for endocarditis, and 95.4%  1.6% and 95.3%  3.7%
for explant and reoperation. Mean pressure gradient values at 5 years ranged from
7.5 to 15.9 mm Hg in the aortic position and at 4 years from 2.0 to 6.9 mm Hg in
the mitral position across all valve sizes.
Conclusions: Clinical and hemodynamic performance of the Mosaic bioprosthesis
were very satisfactory during the first 6 years after clinical introduction.
The Mosaic bioprosthesis (Medtronic Inc, Minneapolis, Minn) is aporcine heart valve with a low-profile stent fixed with glutaraldehydecombining zero-pressure and root-pressure techniques and treatedwith -amino-oleic acid (AOA) to reduce tissue calcification. ThisEuropean multicenter study was intended to evaluate the hemody-namic and clinical performance of the Mosaic valve in the aortic and
mitral positions within the first 6 years after clinical introduction in 1994.
Patients and Methods
This prospective, nonrandomized, multicenter clinical trial of the Mosaic bioprosthesis began
in February 1994. Patients given a diagnosis of valvular heart disease who required replacement
of their aortic or mitral heart valve were eligible to enter the study. Patients undergoing
concomitant procedures and those having active endocarditis at the time of implantation were
entered into the study. Patients who required concomitant valve replacement or who already had
a preexisting prosthetic valve in another position were excluded from enrollment. The study was
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approved by the respective institutional ethics committees, and all pa-
tients gave informed consent to participate. The study was supported
by Medtronic, Inc, the manufacturer of the Mosaic bioprosthesis.
Until May 2000, a total of 461 patients (268 male and 193
female patients) underwent isolated aortic valve replacement
(AVR) and 100 patients (32 male and 68 female patients) under-
went isolated mitral valve replacement (MVR) with the Mosaic
bioprosthesis. The age at implantation ranged from 23 to 89 years
(mean, 70 years) in the aortic group and from 41 to 84 years
(mean, 69 years) in the mitral group. Table 1 summarizes the
preoperative and operative data.
Valve replacement was undertaken by means of standard car-
diopulmonary bypass at mild hypothermia with cold crystalloid
cardioplegia. When the size of the bioprosthesis is being assessed,
it is important to use the manufacturer-supplied Mosaic sizer. Because
of the possibility of the so-called Supra-x placement, the specific
construction of the Mosaic sizer and of the bioprosthesis often allow
the implantation of a one-size-larger valve compared with the con-
ventional supra-annular placement. This makes a significant increase
in the effective flow orifice possible, as mentioned previously.1
The clinical follow-up was done during the initial hospitaliza-
tion for valve replacement, 6 months after the operation, and at
annual intervals. The examination included a hematologic check
and a hemodynamic assessment by means of transthoracic echo-
cardiography. Mean systolic pressure gradients were calculated
with the modified Bernoulli equation. Effective orifice areas were
calculated with the continuity equation:
AVR  [(LVOTDiameter2  0.785  TVILVOT)/TVIAortic Valve]
and
MVR  [(LVOTDiameter2  0.785  TVILVOT)/TVIMitral Valve]
TABLE 1. Preoperative and operative data
Variable
Aortic Mitral
% N % N
Age at implantation (y)
Mean 70 69
Range 23-89 41-84
60 13.0 60 15.0 15
61-70 29.1 134 38.0 38
71-80 52.5 242 44.0 44
80 5.4 25 3.0 3
Sex
Male 58.1 268 32 32
Female 41.9 193 68 68
NYHA classification
Class I 0.9 4 0.0 0
Class II 20.2 93 19.0 19
Class III 66.2 305 58.0 58
Class IV 12.8 59 23.0 23
Aortic valve lesion
Stenosis 61.4 283 16.0 16
Insufficiency 13.4 62 59.0 59
Mixed 25.2 116 25.0 25
Valve size
19 mm 1.3 6 NA NA
21 mm 26.2 121 NA NA
23 mm 38.2 176 NA NA
25 mm 28.0 129 9.0 9
27 mm 5.4 25 25.0 25
29 mm 0.9 4 43.0 43
31 mm NA NA 22.0 22
33 mm NA NA 1.0 1
Concomitant procedures
None 47.5 219 64.0 64
CABG* 35.1 162 24.0 24
Other 17.4 80 12.0 12
Variable Mean SD N Mean SD N
Aortic crossclamp time (min)
All patients 77.1 29.8 461 76.4 28.7 100
Isolated procedure 60.5 17.8 227 68.5 25.8 64
Concomitant procedures 93.4 30.3 233 89.8 28.7 36
CABG, Coronary artery bypass grafts; NA, not available.
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with LVOT defined as left ventricular outflow tract and TVI
defined as time velocity integral.
Prosthetic insufficiency was graded on the basis of color Dopp-
ler assessment as mild, moderate, or severe. The echocardio-
graphic examination has been documented in detail previously.2
In the aortic group 3.7% (n  17) and in the mitral group 2.0%
of the patients (n 2) were lost to follow-up. The mean follow-up
was 3.2 years (range, 0-6.2 years) in the aortic and 2.6 years
(range, 0-6.1 years) in the mitral position. The total follow-up
included 1453.9 patient-years in the aortic group and 256.2 pa-
tient-years in the mitral group, respectively.
The guidelines of the Society of Thoracic Surgeons and The
American Association of Thoracic Surgeons were followed for the
reporting of mortality and valve-related morbidity.3 Linearized
complication rates were calculated by dividing the number of
events by the sum of patient-years expressed as a percentage.
Survival analyses with the Kaplan-Meier product-limit method




In Table 2 the echocardiographically obtained mean pres-
sure gradients and effective orifice areas of the different
valve sizes are depicted.
Postoperative echocardiographic examination revealed
prosthetic regurgitation in 7.6% of the patients after AVR
(34/449, 31 mild and 3 moderate) and in 4.0% (4/100, all
mild) of the patients after MVR. The regurgitation was
transvalvular in 11 (all mild), paravalvular in 17 (15 mild
and 2 moderate), and indeterminate (ie, not assessable by
the echocardiographer) in 6 (5 mild and 1 moderate) pa-
tients in the aortic group and transvalvular and paravalvular
each in 2 patients in the mitral group. Six years after
implantation of the Mosaic bioprosthesis, 11.1% (2/18, 1
mild and 1 moderate, both transvalvular) of the aortic pa-
tient group and no patients in the mitral group showed
prosthetic insufficiency.
Prosthetic Valve–Related Adverse Events
The actuarial rates of freedom from prosthetic valve–related
adverse events and the linearized frequencies are shown in
Table 3.
Mortality
The early mortality (ie, 30 days after the operation), if the
patient was discharged from the hospital or at any time after
implantation if the patient was not discharged from the
hospital, was 2.4% for the aortic group and 1.0% for the
mitral group. The late mortality (ie, 30 days after the
operation), if the patient was discharged from the hospital,
was 11.8% with a linearized rate of 3.7% per patient-year in
the aortic group (on the basis of 1416.6 late patient-years)
and 9.1% with a linearized rate of 3.6% per patient-year in
the mitral group (on the basis of 248.1 late patient-years),
respectively, including valve-related mortality of 0.5% per
patient-year in the aortic group (n  7) and 0.4% per
patient-year in the mitral group (n  1).
The Kaplan-Meier survival functions after AVR and MVR
with the Mosaic bioprosthesis are depicted in Figure 1.
TABLE 2. Echocardiographic data
Valve size
Mean pressure gradient (mm Hg)* Effective orifice area (cm2)
Early follow-up† 5-y follow-up Early follow-up† 5-y follow-up
N Mean  SD N Mean  SD N Mean  SD N Mean  SD
Aortic
19 mm 6 21.6 6.3 4‡ 15.9 5.0‡ 6 1.2 0.2 4‡ 1.2 0.1‡
21 mm 115 15.1 6.8 17 15.2 4.9 115 1.5 0.5 17 1.6 0.3
23 mm 172 12.7 5.0 22 12.8 5.7 172 1.9 0.5 22 1.8 0.3
25 mm 120 11.4 4.4 10 9.5 2.4 120 2.1 0.6 10 2.3 0.5
27 mm 24 10.3 4.0 2 10.4 0.3 24 2.5 0.7 2 2.6 0.6
29 mm 3 18.8 6.4 1 7.5 3 2.0 0.6 1 3.0
All sizes 440 13.0 5.7 52 12.8 5.2 440 1.9 0.6 52 1.7 0.5
Early follow-up† 4-y follow-up Early follow-up† 4-y follow-up
Mitral
25 mm 9 6.5 3.2 2 4.6 1.9 9 1.8 0.5 2 2.6 0.6
27 mm 24 4.7 1.7 4 3.8 0.7 21 1.9 0.8 3 1.5 0.3
29 mm 43 4.2 1.6 9 4.4 1.6 34 1.9 0.5 6 1.8 0.6
31 mm 22 4.9 1.3 3 2.7 0.7 20 1.6 0.5 3 2.1 0.3
33 mm 1 6.0 1 6.0 1 2.5 1 1.8
All sizes 99 4.7 1.8 19 4.1 1.4 85 1.8 0.6 15 1.9 0.5
*Aortic: mean systolic gradient; Mitral: mean diastolic gradient.
†Before hospital discharge or 30 days or less after the operation.
‡One-year result because 19 mm was not followed up later.
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Before implantation of the Mosaic bioprosthesis, 79.0% of
the patients with aortic valve lesions and 81.0% of those
with mitral valve lesions were classified in New York Heart
Association (NYHA) classes III and IV. Six months after
the operation 98.4% in the aortic group and 94.7% in the
mitral group were classified in NYHA classes I and II; 6
years after the operation 100% of the patients in both groups
were so classified. Comparing preoperative state and results
of the 1-year evaluation, 91.0% of the patients in the aortic
group and 83.0% of those in the mitral group had an
improvement in NYHA classification.
Discussion
The Mosaic bioprosthesis is a stented porcine heart valve
designed to minimize the biomodal failure mechanisms of
bioprostheses, mechanical wear, and chemically induced
intrinsic mineralization by means of the combination of
several technologies. It is fitted to a low-profile acetal poly-
mer stent, which is covered with polyester fabric. The
prosthetic tissue is treated with glutaraldehyde to minimize
the consequences of antigenicity after porcine valve implan-
tation.4 The fixation of the Mosaic bioprosthesis is a com-
bination of the so-called zero-pressure and root-pressure
methods: equal pressure is applied to the inflow and outflow
ends of the valve. By this method, the aortic root is pres-
surized to maximize the flow area, and no pressure is
exerted on the leaflets. The natural shape generally is pre-
served, and the disadvantages of low- and high-pressure
fixation (ie, the changed arrangement of collagen and elastic
fibers in the porcine leaflets that leads to altered tissue
extensibility and pliability) can be reduced.5,6 The biopros-
thetic tissue is treated with AOA to mitigate chemical
calcification. AOA is strongly bound to the tissue by form-
ing Schiff base covalent linkages with aldehydes remaining
from the fixation with glutaraldehyde. Chen and associates7
and Duarte and coworkers8 proved the effective retardation
of calcium ion diffusion into the tissue by means of AOA.
Long-term results will show whether the anticalcific com-
petence of the treatment with AOA is effective.
Aortic Position
The mean systolic pressure gradients are very low (ie, 7.5 to
15.9 mm Hg across all sizes). Comparing these results with
those with other established stented bioprostheses, the Mo-
saic performance is equivalent to that of the Hancock mod-
ified orifice II bioprosthesis2 (Medtronic) and the Carpen-
tier-Edwards pericardial valve (Edwards Lifesciences,
Irvine, Calif),9 with the larger sizes (27 and 29 mm) show-
ing excellent hemodynamic function. Our results corre-
sponded to the data published by Thomson and colleagues10
and Wong and associates11 in other Mosaic studies. Because
the construction and implantation of stentless bioprostheses
comprise a different technique, a direct comparison of the
hemodynamic performance would be flawed. However,
generally these Mosaic results approach the results obtained
with stentless devices: Yun and coworkers12 reported mean
systolic pressure gradients of the Freestyle bioprosthesis of
6.7  3.4 mm Hg (21 mm), 2.9  2.3 mm Hg (23 mm),
3.7  2.6 mm Hg (25 mm), and 6.0  4.2 mm Hg (27 mm)
after 4 years, and Westaby and associates13 showed Free-
style results 6 months after the operation of 9.2  3.3 mm
TABLE 3. Freedom from prosthetic valve–related adverse events
Adverse event Position
Early Events* Late Events† Actuarial freedom from event (%  SE)
N %/patients N %/patient-year‡ 1 y 3 y 4/5 y§
Thromboembolism Aortic 3 0.7 8 0.6 98.7 0.5 97.8 0.7 96.6 1.1
Mitral 1 1.0 2 0.8 98.0 1.6 98.0 2.5 94.9 3.3
Valve thrombosis Aortic 0 0.0 4 0.3 99.6 0.3 99.0 0.5 99.0 0.5
Mitral 0 0.0 0 0.0 100 0.0 100 0.0 100 0.0
Structural valve deterioration Aortic 0 0.0 1 0.1 100 0.0 100 0.0 98.8 1.2
Mitral 0 0.0 0 0.0 100 0.0 100 0.0 100 0.0
Nonstructural valve dysfunction Aortic 0 0.0 4 0.3 99.3 0.4 99.3 0.4 98.8 0.7
Mitral 0 0.0 0 0.0 100 0.0 100 0.0 100 0.0
Primary paravalvular leak Aortic 2 0.4 4 0.3 98.9 0.5 98.6 0.6 98.6 0.6
Mitral 0 0.0 0 0.0 100 0.0 100 0.0 100 0.0
Endocarditis Aortic 0 0.0 6 0.4 99.5 0.3 98.4 0.6 98.4 0.6
Mitral 1 1.0 2 0.8 99.0 1.4 99.0 1.4 94.4 3.8
Antithromboembolic-related Aortic 8 1.7 11 0.8 96.4 0.9 96.4 0.9 96.4 0.9
hemorrhage Mitral 4 4.0 5 2.0 93.0 2.6 90.7 3.4 87.1 4.8
Reoperation/explant Aortic 0 0.0 12 0.8 98.6 0.6 97.7 0.8 95.4 1.6
Mitral 0 0.0 2 0.8 98.9 1.1 98.9 1.1 95.3 3.7
*Less than 30 days after the operation.
†Greater than 30 days after the operation.
‡Calculations are based on 1416.6 (aortic) and 248.1 (mitral) late patient-years.
§Five-year results of aortic position and 4-year results of mitral position.
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Hg (21 mm), 5.2  2.3 mm Hg (23 mm), 4.3  2.0 mm Hg
(25 mm), and 4.0  1.9 mm Hg (27 mm). Mohr and
coworkers14 described mean systolic pressure gradients of
the Toronto SPV bioprosthesis (St Jude Medical, Inc, St
Paul, Minn) of 11.1 mm Hg (21 mm and 23 mm), 8.4 mm
Hg (25 mm), 8.9 mm Hg (27 mm), and 7.7 mm Hg (29 mm)
1 week after the operation.
The effective orifice areas of the Mosaic bioprosthesis
after 5 years (1.6-3.0 cm2 across all sizes) are also very
satisfactory. Our results corresponded to the measurements
Figure 1. Survival function: Top, After AVR; bottom, after MVR.
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obtained during other Mosaic studies.11,15 They exceed the
results of Hancock modified orifice II,2 Carpentier-Edwards
Perimount,9 and Medtronic Intact.16 Again, under consider-
ation of the different conditions of stented and stentless
bioprostheses, the 23-mm (2.16  0.65 cm2), 25-mm
(2.38  1.17 cm2), and 27-mm (2.70  0.73 cm2) Freestyle
valves in the series of Yun and colleagues12 4 years after the
operation exceeded our Mosaic results, whereas the Free-
style study of Dumesnil and coworkers15 1 year after the
operation revealed lower effective orifice areas in compar-
ison with these Mosaic results (21 mm, 1.35 0.21 cm2; 23
mm, 1.48  0.33 cm2; 25 mm, 2.00  0.39 cm2; 27 mm,
2.32  0.48 cm2).
As a limitation of the hemodynamic comparisons, it has
to be stated that the sizes of the bioprostheses were taken
over by the definitions given by each manufacturer. The fact
that the manufacturers have chosen to size their prostheses
in different ways can complicate the comparisons of pres-
sure gradients and effective orifice areas because a 23-mm
prosthesis of one manufacturer’s type may not fit the same
anulus as a 23-mm prosthesis from another manufacturer.
This complication should be minimized in further studies by
grouping the valves according to the intraoperative mea-
sured anulus instead of the manufacturer’s description. In
this study the measurements are also referred to the manu-
facturer’s valve size and not to the patients’ anulus. The
actuarial freedom rates from valve-related adverse events
after 5 years are satisfactory. The low incidence of structural
valve deterioration, endocarditis, thromboembolism, and
nonstructural valve dysfunction was especially convincing.
The causes of valve-related death were antithromboembo-
lism-related hemorrhage, valve thrombosis, reoperation for
valve thrombosis (the patient died of multiorgan failure 2
days after reoperation), and reoperation for structural valve
deterioration each in 1 patient and cerebrovascular attack in
3 patients. The cause of the relatively high rate of antithrom-
boembolism-related hemorrhage (freedom after 5 years,
96.4%  0.9%; linearized rate, 0.8% per patient-year)
might be found in the high quota of patients in the aortic
group receiving anticoagulants throughout the 6 postopera-
tive years (61.5% in the 5-year follow-up). The majority
(50.7%) took acetylsalicylic acid (100 mg/d), which was
indicated because of coronary artery disease. Some patients
(10.8%) constantly received warfarin for reasons like atrial
fibrillation and left atrial and ventricular dilation and dys-
function. There certainly were some patients taking warfa-
rin without any reasonable indication but because of miss-
ing information from the general practitioner about the need
for anticoagulation in patients with heart valve bioprosthe-
ses. Combinations of different types of anticoagulants (war-
farin, heparin, acetylsalicylic acid, and ticlid) were seen in
14.6% of all patients only during the early postoperative
period. The freedom rates from reoperation and explanta-
tion of the Mosaic bioprosthesis (95.4%  1.6% after 5
years; linearized rate, 0.8% per patient-year) are average
results when compared with those of other bioprostheses.
The reason for reoperation was primary valve thrombosis in
4 patients, endocarditis in 4 patients, primary paravalvular
leak in 2 patients, and nonstructural valve dysfunction and
structural valve deterioration each in 1 patient.
Mitral Position
The hemodynamic performance of the Mosaic bioprosthesis
in the mitral position is satisfactory. The mean diastolic
pressure gradients after 4 years ranged from 2.7 to 6.0 mm
Hg across all sizes. Lemieux and associates16 reported pres-
sure gradients of the Intact valve in the mitral position 1
year after the operation of 6.18  2.60 mm Hg (25 mm),
5.04  1.86 mm Hg (27 mm), 4.69  1.73 mm Hg (29
mm), and 3.28  0.67 mm Hg (31 mm). The Carpentier-
Edwards pericardial valve showed pressure gradients of 4.1
mm Hg (27 mm) and 3.0 mm Hg (29-33 mm) in a 10-year
series by Aupart and colleagues.17 The effective orifice
areas of the Mosaic bioprostheses in the mitral position are
quite small (1.5-2.6 cm2 across all sizes at 4 years) com-
pared with those of other biologic valves. The Intact valve
showed effective orifice areas of 1.85  0.43 cm2 (25 mm),
1.93  0.39 cm2 (27 mm), 2.33  0.39 cm2 (29 mm), and
2.10  0.26 cm2 (31 mm) 1 year after the operation.16
Aupart and coworkers17 described effective orifice areas of
2.6 cm2 (27 mm), 2.7 cm2 (29 mm), 2.6 cm2 (31 mm), and
3.1 cm2 (33 mm) for the Carpentier-Edwards pericardial
valve. There is no obvious explanation for the small Mosaic
effective orifice areas in the mitral position, and thus this
finding should be critically observed in future studies. The
actuarial freedom rates from valve-related adverse events in
the mitral position 4 years after implantation show good
results: there were no incidences of structural valve deteri-
oration and nonstructural valve dysfunction and a low rate
of thromboembolism and valve-related death. Causes of
valve-related death were antithromboembolic-related hem-
orrhage and permanent neurologic event, each in 1 patient.
Endocarditis was present in 2 patients, resulting in a low
rate of freedom of 94.4%  3.8% after 4 years. Because the
second incidence occurred during the fourth postoperative
year with only 19 patients included in the 4-year follow-up
period, the method of Kaplan-Meier estimates, which is
based on the number of patients at risk, might have contrib-
uted to the unsatisfactory result. The same cause might
underlie the relatively low freedom from reoperation and
explantation (95.3%  3.7% after 4 years) because the 2
valves affected by endocarditis caused the only 2 reopera-
tions and explantations. The relatively low freedom from
antithromboembolism-related hemorrhage might be attrib-
uted to the high rate of patients in the mitral group receiving
anticoagulants postoperatively: 82.5% in the 4-year fol-
low-up period (56.5% for warfarin, 17.4% for acetylsali-
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cylic acid, 4.3% for ticlid, and 4.3% for warfarin and
acetylsalicylic acid). Coronary artery disease was the main
indication for acetylsalicylic acid (100 mg/d) and ticlid. Left
atrial and ventricular enlargement and atrial fibrillation as
results of the mitral lesion were the indications for warfarin.
Again, the missing knowledge of the general practitioner
about the thrombogenicity of bioprostheses might attribute
to the high rate of constant warfarin recipients.
Conclusion
In conclusion, the Mosaic bioprosthesis, both in the aortic
and in the mitral position, showed very good hemodynamic
performance in comparison with that of other stented bio-
prostheses. Compared with other biologic valves, the free-
dom from prosthetic valve-related adverse events was very
satisfactory. Further investigation and data collection will
be necessary to determine long-term results and to decide on
the device’s inferiority or superiority compared with that of
established heart valve devices.
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